Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033703 · ClinicalTrials.gov registry record · Phase 1
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
A Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06033703 is a Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 48 participants, below the 369-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06033703, a Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
Conditions Studied
Interventions
- DRUG Netarsudil Ophthalmic
Study Locations (1)
Massachusetts
- Mass Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033703
The ClinicalTrials.gov registry entry for NCT06033703 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 369-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (87% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 1 intervention - of which Netarsudil Ophthalmic is the first listed.
NCT06033703 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06033703 about?
NCT06033703 is a clinical study titled "Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment". This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safe...
What is the current status of trial NCT06033703?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-01-14. Estimated completion is 2026-12.
What conditions does trial NCT06033703 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy.
What interventions are being tested in trial NCT06033703?
The interventions under investigation include: Netarsudil Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT06033703?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033703 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
RECRUITING · Phase 2
-
Dropless Pars Plana Vitrectomy Study
RECRUITING · Phase 4
-
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Rhegmatogenous Retinal Detachment
All registered trials for this condition
Proliferative Vitreoretinopathy
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.